|
|
|
30 Mar 2006 |
PowderMed’s Therapeutic DNA Vaccine for Chronic Hepatitis B Enters Phase I Clinical Trials in Patients
|
|
27 Mar 2006 |
Crucell Announces Product Approval in Korea for Quinvaxem(TM) Vaccine
|
|
25 Mar 2006 |
Antigenics Reports Phase 3 Results for Oncophage in Kidney Cancer
|
|
25 Mar 2006 |
CancerVax Announces Results of Phase 3 Clinical Trials of Canvaxin(TM) in Patients With Stage III and Stage IV Melanoma
|
|
25 Mar 2006 |
Positive outcome of pivotal Pollinex(R) Quattro Ragweed study - R204
|
|
24 Mar 2006 |
GlaxoSmithKline submits Biologics License Application for FDA approval of Flulaval™
|
|
22 Mar 2006 |
Nabi Biopharmaceuticals Announces Completion of Outside Advisory Panel Assessment of Gram-Positive Program
|
|
10 Mar 2006 |
Mymetics announces NIH Plan to test HIV-AIDS vaccine candidate in non-human primate mode
|
|
10 Mar 2006 |
Nabi Biopharmaceuticals Announces U.S. Fast Track Designation for NicVAX®
|
|
10 Mar 2006 |
Positive Results Of Study Recombinant Bet v 1
|
|
08 Mar 2006 |
Neurocrine Biosciences Announces Results of The Phase II Study in Multiple Sclerosis
|
|
08 Mar 2006 |
GeoVax announces IND “Safe to Proceed Status” granted by the FDA with planned Human Clinical Trials scheduled in April 2006 for its HIV/AIDS Vaccine
|
|
06 Mar 2006 |
Novavax and Bharat Biotech Announce Strategic Alliance for Pandemic Influenza Vaccine Development
|
|
06 Mar 2006 |
Dynavax Presents Positive TOLAMBA Phase 2/3 Results at AAAAI Meeting
|
|
02 Mar 2006 |
Dynavax Provides Update on TOLAMBA Program
|
|
28 Feb 2006 |
AVANT Announces that the European Regulatory Authorities Have Approved Rotarix(R) Rotavirus Vaccine
|
|
27 Feb 2006 |
Genitope Corporation Initiates Clinical Trial to Evaluate MyVax(R) Personalized Immunotherapy in the Treatment of Chronic Lymphocytic Leukemia
|
|
27 Feb 2006 |
Cell Genesys Reports Encouraging Follow-Up Survival Data From Second Phase 2 Trial of GVAX(R) Immunotherapy for Prostate Cancer
|
|
25 Feb 2006 |
European Medicines Agency receives second application for human pandemic influenza vaccine
|
|
24 Feb 2006 |
FDA review date for Merck's investigational shingles vaccine extended to may 25, 2006
|
|
22 Feb 2006 |
Biovest International Submits Amendment Request to FDA for Use of Molecular Remission Data in the Ongoing Pivotal Phase 3 Study to Support Accelerated, Conditional Approval of BiovaxID (TM), a Personalized Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
|
|
22 Feb 2006 |
Enrollment of Phase III study for Intercell’s Japanese Encephalitis Vaccine completed
|
|
21 Feb 2006 |
Ebola DNA Vaccine Produces Immune Responses in All Fully Vaccinated Volunteers in Phase 1 Trial
|
|
17 Feb 2006 |
CSL reveals encouraging results from Australian bird flu vaccine trial
|
|
15 Feb 2006 |
AVANT Announces Start of Phase I/II Clinical Trial of Its Typhoid Fever Vaccine
|
|
15 Feb 2006 |
Acambis announces results from Phase 1 trial of C. difficile vaccine
|
|
10 Feb 2006 |
Therion Completes Phase III Enrollment for PANVAC-VF Pancreatic Cancer Trial; BLA Planned for 2006
|
|
10 Feb 2006 |
Data Indicate that Whole-Inactivated HIV-1 Immunogen Induces HIV-Specific Immune Responses in HIV-Infected, HAART-Naïve Patients
|
|
07 Feb 2006 |
GARDASIL®, Merck's Investigational Cervical Cancer Vaccine, to Receive Priority Review from the U.S. Food and Drug Administration
|
|
07 Feb 2006 |
Nabi Biopharmaceuticals Announces Positive Phase I Results From Its S. epidermidis PS-1 and S. aureus Type 336 Vaccine Clinical Trials
|
|
07 Feb 2006 |
CSL Limited to Apply for License to Market Influenza Vaccine in the U.S.; Major Vaccine Manufacturer to Double Capacity
|
|
04 Feb 2006 |
FDA Approves Merck's Rotateq, the Only Vaccine in the U.S. to Prevent Rotavirus Gastroenteritis, a Leading Cause of Severe Infant Diarrhea
|
|
03 Feb 2006 |
Biologics License Application for Gardasil®, Merck's Investigational Cervical Cancer Vaccine, Is On Track
|
|
01 Feb 2006 |
Vical Opens Phase 2 Trial of DNA Vaccine Against CMV
|
|
01 Feb 2006 |
IDM Closes Enrollment to its EP-2101 Therapeutic Vaccine Trial in Patients With Non-Small Cell Lung Cancer
|
|
01 Feb 2006 |
Pharmexa files the first phase III application
|
|
01 Feb 2006 |
Chiron Reports 2005 Adjusted Earnings of $1.34 Per Share, GAAP Earnings of $0.97 Per Share
|
|
31 Jan 2006 |
Takeda Pharmaceutical Introduces New Measles-Rubella Vaccine
|
|
30 Jan 2006 |
IDM Presents Results of Its Phase I Trial of Its Collidem(R) Dendritic Cell Vaccine in Patients With Advanced Colorectal Cancer at GI-ASCO Meeting in San Francisco
|
|
30 Jan 2006 |
Favrille Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial of FavId for Follicular B-Cell Non-Hodgkin's Lymphoma
|
|
27 Jan 2006 |
Pharmexa starts phase I trial in HIV together with HVTN
|
|
27 Jan 2006 |
Merck KGaA Acquires Full U.S. Rights to BLP25 Liposome Vaccine
|
|
26 Jan 2006 |
Nabi Biopharmaceuticals Provides Update on Strategic Direction of NicVAX(TM) Program
|
|
26 Jan 2006 |
Generex Biotechnology announces interim results of clinical breast cancer trial
|
|
26 Jan 2006 |
DOR BioPharma Achieves Manufacturing Milestone in Development of RiVaxTM DOR and its collaborators achieve 2nd milestone ahead of schedule.
|
|
25 Jan 2006 |
BiovaxID(TM) Yields 89% Survival in Patients with Aggressive Non-Hodgkins Mantle Cell Lymphoma at Median Follow-up of 3.8 Years
|
|
24 Jan 2006 |
Ullevål University Hospital and GemVax collaborates on translational research
|
|
18 Jan 2006 |
Inovio Biomedical to Develop Vaccine for Hepatitis C in Partnership with Tripep AB
|
|
11 Jan 2006 |
Pharmexa obtains approval in Russia
|
| |
|
Results 551 - 599 of 599 |
